Table 1 Clinical characteristics
From: Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
| Â | All Casesa | Pre-ipi approval | Post-ipi approval | Post-ipi approval | |
|---|---|---|---|---|---|
(n = 300) | (n = 94) | (n = 206) | (n = 206) | ||
ICI Treated | ICI Not Treated | ||||
Age at initial cutaneous melanoma diagnosis (Years, %) |  |  |  | (n = 160) | (n = 46) |
  < 30 | 9 (03.0) | 5 (05.3) | 4 (01.9) | 2 (01.3) | 2 (04.3) |
 30–39 | 25 (08.3) | 11 (11.7) | 14 (06.8) | 9 (05.6) | 5 (10.9) |
 40–49 | 49 (16.3) | 15 (16.0) | 34 (16.5) | 26 (16.3) | 8 (17.4) |
 50–59 | 69 (23.0) | 25 (26.6) | 44 (21.4) | 37 (23.1) | 7 (15.2) |
 60–69 | 68 (22.7) | 17 (18.1) | 51 (24.8) | 40 (25.0) | 11 (23.9) |
 70–79 | 51 (17.0) | 13 (13.8) | 38 (18.4) | 31 (19.4) | 7 (15.2) |
  ≥ 80 | 29 (09.7) | 8 (08.5) | 21 (10.2) | 15 (09.4) | 6 (13.0) |
 Mean | 59 | 56 | 60 | 61 | 58 |
Year of diagnosis (Range) | 1974–2016 | 1974–2010 | 1989–2016 | 1990–2016 | 1989–2016 |
Sex | |||||
 Female | 111 (37.0) | 36 (38.3) | 75 (36.4) | 53 (33.1) | 22 (47.8) |
 Male | 189 (63.0) | 58 (61.7) | 131 (63.6) | 107 (66.9) | 24 (52.2) |
Race | |||||
 White | 293 (97.7) | 94 (100.0) | 199 (96.6) | 154 (96.3) | 45 (97.8) |
 Other | 2 (06.0) | 0 (00.0) | 2 (01.0) | 1 (00.6) | 1 (02.2) |
 Unknown | 5 (01.7) | 0 (00.0) | 5 (02.4) | 5 (03.1) | 0 (00.0) |
Vital status at last follow up | |||||
 Alive | 136 (45.3) | 16 (17.0) | 120 (58.3) | 92 (57.5) | 28 (60.9) |
 Dead | 164 (54.7) | 78 (83.0) | 86 (41.7) | 68 (42.5) | 18 (39.1) |
Year of bx proven Stage IV disease (range) | 1992–2017 | 1992–2011 | 2011–2017 | 2011–2017 | 2011–2017 |
Months of follow up (Median)b | 16.2 | 16.5 | 16.2 | 16.2 | 15.5 |
  < 1 | 13 (04.3) | 0 (00.0) | 13 (06.3) | 10 (06.3) | 3 (06.5) |
 3 | 122 (40.7) | 0 (00.0) | 122 (59.2) | 104 (65.0) | 18 (39.1) |
 6 | 74 (24.7) | 3 (03.2) | 71 (34.5) | 46 (28.8) | 25 (54.3) |
 10 | 42 (14.0) | 42 (44.7) | 0 (00.0) | 0 (00.0) | 0 (00.0) |
  > 10 | 49 (16.3) | 49 (52.1) | 0 (00.0) | 0 (00.0) | 0 (00.0) |
 Median | 4.4 | 10 | 3 | 2.8 | 4.2 |
Years from diagnosis to bx proven Stage IV disease (Median) | 1.1 | 1.5 | 1 | 1 | 0.7 |
Received BRAF TKI (Yes, %) | 25 (08.3) | 0 (00.0) | 25 (12.1) | 19 (11.9) | 6 (13.0) |
Mo from specimen collection to BRAF TKI (Median) | 6·5 | N/A | 6·5 | 8 | 6 |
Checkpoint inhibitor | |||||
 Ipilimumab |  | 72 (45.0) | N/A | ||
 Pembrolizumab |  | 68 (42.5) | N/A | ||
 Nivolumab |  | 7 (04.4) | N/A | ||
 Ipilimumab + Nivolumab |  | 13 (08.1) | N/A | ||
Time to progression (median days) | Â | 77.5 | N/A | ||
Progression free survival (median days) | Â | 129.5 | N/A | ||